{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/80872"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/80872","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"Advancement of a Liposome-Based Vaccine Against Streptococcus Pneumoniae","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Hill, Andrew"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Pfeifer, Blaine","Chemical and Biological Engineering"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-10-29T16:47:45Z","date_published":"2019-10-29T16:47:45Z","updated_at":"2026-07-27T19:05:25Z","subjects":["chemical engineering"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/80872","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Pfeifer, Blaine","Chemical and Biological Engineering"]},{"key":"dc:creator","label":"Author","values":["Hill, Andrew"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-10-29T16:47:45Z","2019","2019-07-30 19:12:06"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["chemical engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/80872"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","Streptococcus pneumoniae is a major bacterial pathogen that is a leading cause of community-acquired pneumonia (CAP), bacterial meningitis, bacteremia, and otitis media (OM). The aforementioned illnesses caused by S. pneumoniae’s transition from asymptomatic carriage (i.e., colonization of the nasopharynx) to disease are associated with a mortality rate between 3-10% in adults and 12-25% in elderly patients in the United States. Current commercial vaccines target the capsular polysaccharides (CPS) of S. pneumoniae, which decorate the surface of the bacteria during colonization, and thus seek to prevent the circulation (i.e., herd immunity) of the serotypes associated with the highest risk for invasive disease. However, despite pneumococcal glycoconjugate vaccines significantly reducing disease, emerging studies indicate that serotype replacement represents a critical clinical challenge.The work presented here outlines the attempt to advance a pneumococcal vaccine coined “liposomal encapsulation of polysaccharides” (LEPS) to overcome current limitations associated with current vaccines. The work presented within this dissertation is designed to refine the formulation of the LEPS vaccine against S. pneumoniae and to address various concerns raised by experts within the pneumococcal vaccine field. Some of the concerns this work seeks to address involve the risk of off-target effects towards the microbiome, the inclusion of a His-tagged protein within the vaccine design, insufficient serotype coverage, limited assessment of vaccine toxicity, and the lack of an established in vitro assay for assessing efficacy against biofilm-released pneumococci (BDP). In summary, this dissertation presents the work performed to develop a second generation LEPS pneumococcal vaccine to late-stage preclinical development."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Advancement of a Liposome-Based Vaccine Against Streptococcus Pneumoniae"]}]}],"canonical_facts":{"dc:contributor":["Pfeifer, Blaine","Chemical and Biological Engineering"],"dc:creator":["Hill, Andrew"],"dc:date":["2019-10-29T16:47:45Z","2019","2019-07-30 19:12:06"],"dc:description":["Ph.D.","Streptococcus pneumoniae is a major bacterial pathogen that is a leading cause of community-acquired pneumonia (CAP), bacterial meningitis, bacteremia, and otitis media (OM). The aforementioned illnesses caused by S. pneumoniae’s transition from asymptomatic carriage (i.e., colonization of the nasopharynx) to disease are associated with a mortality rate between 3-10% in adults and 12-25% in elderly patients in the United States. Current commercial vaccines target the capsular polysaccharides (CPS) of S. pneumoniae, which decorate the surface of the bacteria during colonization, and thus seek to prevent the circulation (i.e., herd immunity) of the serotypes associated with the highest risk for invasive disease. However, despite pneumococcal glycoconjugate vaccines significantly reducing disease, emerging studies indicate that serotype replacement represents a critical clinical challenge.The work presented here outlines the attempt to advance a pneumococcal vaccine coined “liposomal encapsulation of polysaccharides” (LEPS) to overcome current limitations associated with current vaccines. The work presented within this dissertation is designed to refine the formulation of the LEPS vaccine against S. pneumoniae and to address various concerns raised by experts within the pneumococcal vaccine field. Some of the concerns this work seeks to address involve the risk of off-target effects towards the microbiome, the inclusion of a His-tagged protein within the vaccine design, insufficient serotype coverage, limited assessment of vaccine toxicity, and the lack of an established in vitro assay for assessing efficacy against biofilm-released pneumococci (BDP). In summary, this dissertation presents the work performed to develop a second generation LEPS pneumococcal vaccine to late-stage preclinical development."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/80872"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["chemical engineering"],"dc:title":["Advancement of a Liposome-Based Vaccine Against Streptococcus Pneumoniae"],"dc:type":["Text","Dissertation"]},"updated_at":"2026-07-27T19:05:25Z"}